W hat should I disclose and whe n? According to the Institute of Medicine, a medical error is "the failure of a planned actio n to be com pleted as intended" [i.e., error of exec ution] or "the use ofa wro ng plan to achieve an aim" [i.e., an error of planning].' An adverse event is an injury caused by medical manage ment rather than the unde rlying condition of the patient. An adverse event attributable to erro r is a "preventable adverse event.'? Not all errors result in adverse eve nts; sometimes a mistake is made but the patient does not suffer harm as a result. And not all adverse even ts are caused by error.
For exa mple, side effec ts of appro pr iately prescribed and administe red chemotherapy are an exa mple of adverse eve nts not caused by error.
Medical errors should be disclosed to patients for a number of reasons . Because of their fiduciary relationship with patients, physicians have an eth ical responsibility to disclose erro rs to them . To withhold this information undermines the public trust in medicine and damages the therapeutic relationship between physician and patient. In fact, patients may be caused additional, avoidable harm by failure to disclose because they lack information that wou ld allow them to rece ive appropria te treat ment should further complications arise.'
Talking to patients about er rors Focus-group research indicates that there is strong agree-410 ment among physicians that patients should be told about any error that has caused harm or requires follow -up testing or treatme nt.' However, physicians participating in this study expressed uncertainty about whether to disclose errors when there was no harm or when the harm was trivial. Also, physicians perceived a numb er of barriers to disclos ing errors, including fear of litigation, fear of bei ng reported to a publi c registry, and not knowin g how to talk to patients about errors.'
Few physicians receive training in how to disclos e and disc uss adverse eve nts with patients. Chan et al reviewed the literature on error disclosure and surveyed patients about their information needs related to errors, and they deve loped a five-poi nt framework for effective error disc losure.' Th is framewo rk includes: (I) an objective exp lanation of the medical facts related to the error, (2) honesty and truthfu lness , (3) empathy, (4) a discussion of how future adve rse events will be prevented for all patien ts, and (5) general commun ication skills, such as listening, responsiveness, and checking for understanding. When observing physicians in standar dize d error-disclosure sce narios, Chan and colleagues found that surgeo ns scored high on describing the medical facts and on honesty and truthfulness, but lower on characteristics of empathy and on steps that would be taken to prevent errors from occurr ing in the future.' These weaknesses could be addressed through additional training, both in how to communicate errors and in error-prevention strategies. Also, tools are avai lable to help physicians learn disclosure skills. For example, the
Georgia Hospital Association's Partnership for Health and
Accou ntab ility has a free video , Discussing Unanticipated Outcom es and Disclosing Medica l Errors . The video contains advice on how to comm unicate wit h patients when disclosing errors and models error-disclosure conversations between physicians and patients.
W ha t effect does disclosure have on liability?
Fear ofliabi lity is not a trivial concern. In a rece nt survey, 77% of hospitals indica ted that malprac tice fear was the principal barrier to erro r disclosure.' Ma lprac tice liability and insurance costs have become so high that they have caused physicians to mov e their practices to other states and, in some states , institute work stoppages.' Althou gh ENT-Ear, Nose & Throat Journal s July 2006
The followingtreatment-related adverse events were eachreportedin a single patient:tympanostomyt ube blockage; ear pruritus; tinnitus; oral moniliasis; cryi ng; dizziness; and erythema. Acute Otitis Extema: The followingtreatment-related adverse eventsoccurred in0.4% or more of the patients withintacttympanic membranes.
Pregnancy
Teratogenic Effects. Pregnancy CategoryC: Reproduction studieshave beenperform ed in rats andmice using oral doses of upto 100 mg/kg and IV doses up to 30mg/kg andhave revealed no evidenceof harm to the fetus as a result of ciprofloxacin. In rabbits, ciprofloxaci n (30 and 100mg/kg orally) produced gastrointestinal disturbances resulting in maternal wei ght loss andan increased incidence of abortion, but no teratoge nicitywasobse rved at either dose. After intravenous admi nistration ofdoses upto20 mg/ kg, no maternal toxicity wasproduced in the rabbit, and no embryotoxicity or teratogenicitywasobserved. Cort icosteroids are generally teratog enic in laboratory animalswhenadministered systemicallyat relativelytowdosage levels. The more potentcorti costeroidshave beenshown tobeteratogenic after derma l application in laboratory animal s. Animal reproduct ionstudies havenot been conducted with CI P RO O EXÕ tic. Noadequate and well controlled studieshave beenperformed in pregnant women. Caution should be exercisedwhen CIPROOEX" Otic is used bya pregnant woman. Nursing Mothers:Ciprofloxacinand cort icosteroids, asa class,appearinmilkfollowingoral administrati on. Dexamethasone in breast milkcould suppre ssgrowth, interfere withendogenous corticosteroidprodu ction, orcause other untoward effects. It isnotknownwhether topical otic administration of ciprofloxacin or dexamethasone could result in sufficient systemic absorption to produce detectable quantities in human milk. Because of thepotential forunwanted effects innursing infants, a decisionshould bemade whether to discontinue nursing or to discontinue thedrug, taking into account the importance of thedrug to the mother. Pediatric Use: The safety and efficacy of CIPRO OEX" Otic have been established in pediatric patients 6months and older(937patients)in adequate andwell-controlled clinical trials. Although no data are available onpatientslessthanage6 months, therearenoknownsafetyconcerns ordi fferencesinthedi sease process inthis populationthat would preclude useof this product.(See DOSAGEANDAOMINISTRATION.) No clinically relevant changesin hearingfunctionwereobservedin 69pediatric patients (age 4to 12years) treated with CIPROOEX " Otic and tested for audiometric param eters. ADVER SE REACTIONS In Phases II and III clinical trials, a total of 937 patients were treated with CIPROOEX" Otic. This included 400 patients with acuteotitis media with tympanostomy tubes and 537 patients with acute otitis exte rna . The reportedtreatment-relatedadverse event sare listedbelow: Acute Ot itis Media in pediatric patients with tympanostomy tubes: The following treatment-related adverseeventsoccurre din0.5% or more of thepatientswithnon-intacttympanic membranes.
The following treatment-related adverse events wereeach reported in a Single patient ear discomfort; decreased hearing; and ear disorder (tingli ng). Among culture posi tive pati ents, clinical cures were 90% for CI PROOEXo Otic compar ed to 79% tor ofloxacin solution, 0.3%. Microbiological eradication rates for these patients in the same clinical trial were 91% for CIPROOEX " Otic compared to 82% for ofloxaci n solution, 0.3%. In 2 randomized mul ticenter , controll ed clinical trials, CI PR O OEX~Otic dosed 2 times per day for 7 days demonstrated clinical cures in 87% and 94% of per protocol evaluable AO E patients, respectively, compared to 84% and 89%, respectively, for otic suspension containing neomycin 0.35%, polymyxin B 10,000 IU/mL, and hydrocortisone 1.0% (neo/poly/HC). Among culture positive patients clinical cureswere 86% and 92% for CI PROOEX o Otic compared to 84% and 89%, respectively, for neo/poly/HC. Microbiological eradication rates forthesepatientsinthe same clinicaltrials were86%and 92%for CIPROOEX" Otic compared to 85% and85%,respectively, for neo/poly/HC. . th h · CIPRODEX!I (ciprofloxacin 0.3% and de~a met has? ne . 0 te~1 e tic~spens l 9n c on t a l n~. e synt enc broad-spe ctrum antibacterial aQent, cl p~of l o xac l n hydrochloride, cornblned With the an t l ' l n f l a m ma t oc orticosteroid, dexamethasone. In a s!enle, preserved sus pen~lO n for o t~c use. EachmLof CIPRO DEX Otic contains ciproflaxacin hydrochlOride [equivalent to~mg. c l p~o f l ox~c m base). 1.mg~exa m~thasone. and 0.1mgbenzalkonium chloride as a pre~erv a ! l v e. T~e mactve ingredients~re boric acid, s~dJu m chl oride,hydroxyethyl cellul ose,tyloxapol, acsuc acid, scdium acetate, edetate dlscdium, and purified water . Sodiumhydroxide or hydrochloric acid may be added for adjustment of pH. Ciprofloxacin, a f1uoroquinol one is available. as the monohydrochlor ide monohydrate. sal t of t -cvclo-propyl_6_f1uoro_14_dihydro_4_oxo_ 7_{I_pl perazlnyl)_3_qulnohnecarboxyhc acid, The empi rical formula IS C17HI8FN303.HCI.H20. Dexamethasone, 9-f1uoro-l l!be ta).17,2Hrihydroxy-16(alpha)-methylpregna-l, 4-diene-3,20 -dione, is an anti-inflammatory corticosteroid, The empiri cal formula ISCnH29F05. CUNICALPHARMACOLO GY Pharmacokinetics: Following a single bilateral 4-drop (total dose = 0.28ml, 0.84 mgciprofloxacin,0.28 mg dexamethasone)topical otic dose of C I P RO OEX~Otic to pediatric patients after tympa nostomy tube insertion.measurable pl asma concentrations of ciprofloxacin and dexamethasonewere observed at 6 hours following administrationin 2of 9 patientsand 5 of 9 patients, respectively. Mean ± SO peak plasma concentrations of ciprofloxacin were 1.39 ± 0.880 ng/mL (n=9). Peak plasma concentrations ranged from 0.543 ng/mL to 3.45 ng/mL and were on average approximatel y 0.1% of peak plasma concent rations achieved with an oral dose of 250-mg Ĩ J. Peak pl asma concentrations of ciprofloxacin were observe d within 15minutes to 2 hours post dose application. Mean ± SOpeak plasma concentrationsof dexametha sonewere 1.14 ± 1.54ng/mL(n=91. Peak plasmaconcentrations ranged from 0.135 ng/mLto 5.10 ng/mLand were on average approximately 14% of peak concentrations reported in the literature following anoral 0. 
OOSAGE ANOAOMINISTRATION

C'&JOPROOEX
PRECAUTIONS
General: Aswith otherantibacteria l preparations, use ofthisproductmay result in overgrowth ofnonsusceptible organisms,including yeast and fungi. If the infection is not improved after oneweekof treatment, cultures should beobtained to guidefurther treatment. If otorrhea persists aher a full courseof therapy, or iftwoormoreepisodes ofotorrheaoccur withinsixmonths, further evaluat ionisrecommendedtoexclude an underlying condi tion such as cholesteatoma,foreign body, or a tumor. The systemi c administration of quinolones, including ciprofl oxacin at doses much higher than given or absorbed by the otic route, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals ofvariousspecies. Guinea pigs dosed inthemiddle ear with C1PRODEXI!l Ot ic for one month exhibited no drug-related structural or functional changes of the cochlear hair cells and no lesions in the ossicles. CIPROOEXo Otic was also shown to lack dermal sensitizing potential in the guinea pi2 whentestedaccording to the method of Buehler. No signsof local irritationwere foundwhen CIPROOEX Ot ic wasapplied topicall y inthe rabbit eye. Information for Patients: For otic use only. (Thi s productis not approved for use in the eye.) Warmthe bottle in your hand for one to two minutes prior to use andshake well immediately before using. Avoid contaminating the tip with material from the ear, fingers, or other sources.Protect from light. If rashor allergic react ionoccurs, discontinue use immediately and contact you r physician. It is veryimportantto usethe ear drops for aslong as the doctorhas instructed, even if thesymptomsimprove. Discardunused portionaftertherapyiscompleted. Acute OtitisMediainpediatric patients with tympanostomy tubes: Prior to administration of CIPROD EX o Otic in patients(6 months and older) with acute otitis media throughtympanostomy tubes , the solution should be warmed by holding the bottle inthe hand for oneor two minutesto avoid di zziness which may result from the instillation of a cold solution. The patient should lie with the affected ear upward, and then the drops should be instilled. The tragusshould then be pumped 5 times by pushing inward to facilitate penetration of the drops into the middle ear. This position should be maintained for 60seconds. Repeat, if necessary, for the opposite ear (see DOSAGE ANOAOMINISTRATION). Acute Otitis Externa: Prior to administration of CIPROO EXÕ tic in pati ents with acute otitis externa, the solution should be warmed by hol ding the bottl e in the hand for one or twominutes to avoid diuiness which mayresul t from theinstillation of a cold solution.
Thepatient should lie withthe affected ear upward, and then the drops should be instilled. This position should be maintained for 60seconds to facilitate penetration of the drops into the ear canal. Bepeat, If necessary, for the opposite ear (see DOSAGEAND ADMINISTRATION). Orug Interactions: Specific drug interaction studies have not been conducted with CI PROOEX o Otic. Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term carcinogenicity studies in mi ce and rats have been completed for ciprofloxa cin. Aher daily oral doses of 750 mg/kg (mice) and 250 mg/kg (rats) were administered for up to 2 years, there was no evi dence that ciprofloxacin had any 
Adverse Event
Incidence ( One additional benefit of this pol icy of extreme honesty is that whe n the patient or famil y perceive s an adverse event and the hospital investigation finds no wrongdoing on the hospital's part, the hospital politely, but firml y, refuses to settle. The incidence of frivolous lawsuits has the refo re decl ined , since local attorney s have learn ed that they 're not likel y to win a su it when the hospital has refu sed to settle; "
According to the Sorry Works! Coalition , similar results are bein g reported by academic and pri vate-sector institutions across the country as the y implement and monitor full- 
